Daiichi Sankyo Builds Vaccines Business Via FluMist Deal
This article was originally published in PharmAsia News
Executive Summary
Daiichi Sankyo is adding to its vaccines portfolio in Japan through a deal to market in the country AstraZeneca's nasally administered quadrivalent flu product FluMist.